Pregnancy after treatment for cervical cancer precursor lesions in a retrospective matched cohort

PLoS One. 2015 Feb 11;10(2):e0117525. doi: 10.1371/journal.pone.0117525. eCollection 2015.

Abstract

Objective: To determine whether treatments for precancerous cervical lesions were associated with lower pregnancy rates compared to rates in unexposed women and women who had a diagnostic cervical biopsy or colposcopy.

Design: Matched, retrospective cohort study.

Setting: Kaiser Permanente Northwest (KPNW), an integrated healthcare delivery system in Oregon and Washington.

Patients: Women 14 to 53 years old with KPNW enrollment during the period 1998 through 2009.

Main outcome measure: Pregnancy after exposure or index date. Pregnancy was defined using a validated algorithm and electronic medical records data.

Results: We observed 570 pregnancies following cervical treatment in 4,137 women, 1,533 pregnancies following a diagnostic procedure in 13,767 women, and 7,436 pregnancies in a frequency-matched sample of 81,435 women unexposed to treatment or diagnostic procedures. After adjusting for age and contraceptive use, we observed a higher rate of pregnancies in the treatment group compared to unexposed women (hazard ratio (HR) = 1.42, 95% confidence interval (CI): 1.30-1.55), but no difference in pregnancy rates between the treatment and diagnostic procedure groups (HR = 1.03, 95% CI: 0.93-1.13).

Conclusions: No adverse effects of cervical procedures on subsequent rates of pregnancy were observed in this cohort with up to twelve years of follow-up time.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Cohort Studies
  • Female
  • Humans
  • Middle Aged
  • Precancerous Conditions / diagnosis
  • Precancerous Conditions / physiopathology*
  • Precancerous Conditions / therapy*
  • Pregnancy
  • Pregnancy Rate*
  • Retrospective Studies
  • Uterine Cervical Neoplasms / pathology*
  • Young Adult

Grants and funding

GlaxoSmithKline Biologicals SA (www.gsk.com) funded this study and was involved in all stages of study conduct, including analysis and interpretation of the data and development of this manuscript. SW and AN received grants from GlaxoSmithKline to conduct the study.